A*STAR

ATLATL Innovation Center: Pioneering Collaboration at J.P. Morgan 2024

Retrieved on: 
Tuesday, January 16, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Multimedia, City, Partnership, Therapy, A*STAR, Conference

ATLATL had a wonderful showcase in JPMorgan Healthcare Conference, brimming with momentum and a sharpened focus on driving healthcare innovation globally.

Key Points: 
  • ATLATL had a wonderful showcase in JPMorgan Healthcare Conference, brimming with momentum and a sharpened focus on driving healthcare innovation globally.
  • ATLATL's presence wasn't simply about showcasing established offerings; it was about forging strategic partnerships and laying the groundwork for a collaborative future.
  • Through their collaborative spirit, global reach, and unwavering scientific dedication, ATLATL is poised to play a central role in driving innovation and bringing life-saving therapies to fruition.
  • The echoes of progress reverberate throughout the region, and ATLATL stands as a key player, amplifying the potential of transformative medical solutions.

ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics

Retrieved on: 
Thursday, December 21, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Partnership, Agency, Drug discovery, EDDC, Multimedia, Antibody, TCR, A*STAR, Catalog, Engineering, Cell, Patient, Experimental drug

ImmunoScape , a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, announced a partnership with the Experimental Drug Development Centre (EDDC) , Singapore's national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR).

Key Points: 
  • ImmunoScape , a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, announced a partnership with the Experimental Drug Development Centre (EDDC) , Singapore's national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR).
  • View the full release here: https://www.businesswire.com/news/home/20231221788895/en/
    ImmunoScape’s core antigen-specific T cell immune profiling technology was developed at A*STAR’s Singapore Immunology Network and is exclusively licensed from A*STAR.
  • In this new partnership, ImmunoScape will leverage its catalog of highly potent tumor-specific TCR candidates for the joint development of innovative off-the-shelf TCR-based bispecific molecules with EDDC.
  • EDDC will apply its expertise in therapeutic protein design and antibody engineering to develop these novel TCR-based bispecific molecules.

65LAB Launches in Partnership with Evotec SE and Backed by Leading Global Investors to Advance Drug Discovery and New Company Creation in Singapore

Retrieved on: 
Thursday, October 5, 2023
Transfer, Partnership, Public Service Enterprise Group, NUS, Duke–NUS Medical School, National university, Drug development, Development, Polaris Partners, Innovation, A*STAR, Therapy, Lightstone, University, National University of Singapore, Academic Partnerships, Patient, Bayer, Growth, Assistant professor, Duke University, Public sector, Drug discovery, STAR, Agency, Technology transfer, Tutoring, Pharmaceutical industry, Research, Evotec, Science

The first collaboration of its kind in Singapore, 65LAB was initiated by Lightstone Ventures with Evotec to leverage the global capabilities of its partners – including financing, networks, company creation, and drug development expertise -- to identify and accelerate the commercialization of the most promising research from top academic and R&D institutions in Singapore, the Agency for Science, Technology and Research (A*STAR), the National University of Singapore (NUS) and Duke-NUS Medical School (a collaboration between Duke University and NUS). 65LAB aims to combine Evotec's end-to-end integrated R&D platform and product development strength with Singapore's first-class academic and translational science, it's growing biotech infrastructure and capabilities to ultimately create breakthrough therapies with a global health impact.

Key Points: 
  • 65LAB was founded to establish a model of long-term partnership to foster future company growth and the development of Singapore's biotech ecosystem.
  • 65LAB selects promising academic projects and invests up to US$1.5 million in each project over the course of 18-24 months.
  • Upon completion, projects will be evaluated by 65LAB's board of global investors for further investment and the creation of new companies.
  • Dr. Thomas Hanke, EVP Head of Academic Partnerships at Evotec, said: "Singapore has multiple world-renowned institutions for basic research in the life sciences.

A*STAR’s Genome Institute of Singapore, NanoString and Next Level Genomics Establish Joint Lab to Advance Studies of Complex Diseases with Spatial Genomics

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Genetics, Other Science, Research, Science, Partnership, STAR, DSP, Genomics, Infection, NLG, Cancer, Multimedia, Biomarker, Cell, Protein, HIV disease progression rates, A*STAR, Neuroscience, NanoString Technologies, Gene, GIS, Disease, Vaccine

The new lab, called the SpACE-Dx lab (Spatial Atlas of Clinical Evolution of Disease), will harness spatial multiomic (gene and protein expression) technologies to drive research in complex diseases, with a primary focus on cancer.

Key Points: 
  • The new lab, called the SpACE-Dx lab (Spatial Atlas of Clinical Evolution of Disease), will harness spatial multiomic (gene and protein expression) technologies to drive research in complex diseases, with a primary focus on cancer.
  • View the full release here: https://www.businesswire.com/news/home/20231003819883/en/
    The SpACE-Dx lab will be situated within A*STAR’s GIS facility and be accessible to the local research community.
  • It aims to foster collaboration and accelerate advancements in spatial genomics research.
  • “Next Level Genomics is honoured to be part of this collaborative effort to add cutting-edge technology from NanoString to A*STAR’s research efforts.

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Retrieved on: 
Tuesday, August 1, 2023
GMP, China National Intellectual Property Administration, Patent, Antigen, CNIPA, Partnership, IPSC, NKT, STAR, National University Hospital, Clinical trial, Cell, Immunotherapy, CN, NUH, Agency for Science, Technology and Research, Hematological Cancer Research Investment and Education Act, Biological patents in the United States, Risk, A*STAR, Cytomics, Blood, Agency, Cancer, Same, Outline of health sciences, Health Sciences Authority, T, HSA, NKG2D, Pharmaceutical industry, Vaccine, Science, Research

SINGAPORE, Aug. 1, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, which is exclusively licensed from the Agency for Science, Technology and Research (A*STAR), has been granted a patent by the China National Intellectual Property Administration (CNIPA).

Key Points: 
  • The Company holds an exclusive, worldwide license, for use in immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • CytoMed's CAR-γδ T cell technology has been developed as an investigational cancer therapy to target NKG2D ligands, a type of stress-induced cancer antigens.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive a novel synthetic γδ NKT cells for the treatment of various types of cancers.
  • A patent for this proprietary technology has already been granted in Japan, and this asset is under preclinical development.

European Extracellular Vesicles & Nanoparticle-based Therapeutics Conference 2023: Explore Cutting-Edge Innovations and Therapeutic Opportunities (Rotterdam, Netherlands - November 13-14, 2023) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 25, 2023
Other Health, Research, Pharmaceutical, Medical Devices, Technology, Hospitals, Science, Surgery, Nanotechnology, Biotechnology, Other Science, Health, EV, University, Exhibition, Engineering, Associate professor, University Medical Center, Head, Therapy, Eurostar, University of Bordeaux, Medical biology, Teaching hospital, Seminal vesicles, A*STAR, Transfusion medicine, Faculty, Nanoparticle, International Society for Extracellular Vesicles, Vaccine, Conference, Medical device, Management, Pharmaceutical industry, Hospital, Nanomedicine

The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.
  • Welcome to the Extracellular Vesicles (EV) & Nanoparticle-based Therapeutics Europe 2023 Conference to be held 13-14 November 2023 at the Hilton Rotterdam, The Netherlands.
  • At this conference we bring together speaking faculty who represent academic thought leaders as well as leading industry participants translating technologies into commercial offerings and innovations in the field.
  • The conference features extensive networking opportunities and is held 7-minutes walk from Rotterdam Centraal with fast and very easy access to Amsterdam-Schiphol with worldwide connections as well as the Eurostar to London plus fast-trains to Antwerp, Brussels and Paris.

European Extracellular Vesicles & Nanoparticle-based Therapeutics Conference 2023: Advancing Therapeutics - Industry Giants and Academic Experts Converge (Rotterdam, Netherlands, November 13-14, 2023)

Retrieved on: 
Monday, July 24, 2023
EV, University, Exhibition, Engineering, Associate professor, University Medical Center, Head, Therapy, Eurostar, University of Bordeaux, Medical biology, Teaching hospital, Seminal vesicles, A*STAR, Transfusion medicine, Faculty, Nanoparticle, Research, International Society for Extracellular Vesicles, Vaccine, Conference, Management, Pharmaceutical industry, Hospital, Nanomedicine

DUBLIN, July 24, 2023 /PRNewswire/ -- The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 24, 2023 /PRNewswire/ -- The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.
  • Welcome to the Extracellular Vesicles (EV) & Nanoparticle-based Therapeutics Europe 2023 Conference to be held 13-14 November 2023 at the Hilton Rotterdam, The Netherlands.
  • At this conference we bring together speaking faculty who represent academic thought leaders as well as leading industry participants translating technologies into commercial offerings and innovations in the field.
  • This conference features scientific presentations, industry technology spotlight presentations, posters as well as a co-located exhibition, and the conference features companies in this field developing technologies, products and services as well as moving (clinical) candidates forward into the clinical trials regimen.

Significantly Reduce Manufacturing Cost and Increased Local Production: SCG Cell Therapy Opens State-of-the-art Cell Therapy Manufacturing Facility and R&D Centre in Singapore

Retrieved on: 
Wednesday, July 19, 2023
GMP, White House, Biotechnology, IPSC, Cell therapy, Innovation, Infection, Cell, SCG, Government, Ministry, Agency for Science, Technology and Research, Patient, CGMP, Risk, A*STAR, Agency, Outline of health sciences, Cancer, EDB, Growth, The Singapore Economic Review, R, Health Sciences Authority, Christy, FDA, HSA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ministry of Trade and Industry, Food, Pharmaceutical industry, Fine chemical, State, Science, Research

SCG Cell Therapy celebrates the opening of its new Cell Therapy Manufacturing Facility and R&D Centre, launching a new first-of-its-kind automatic cell therapy manufacturing system in Singapore, pioneering Singapore's Manufacturing 2030 Vision.

Key Points: 
  • SCG Cell Therapy celebrates the opening of its new Cell Therapy Manufacturing Facility and R&D Centre, launching a new first-of-its-kind automatic cell therapy manufacturing system in Singapore, pioneering Singapore's Manufacturing 2030 Vision.
  • Facility will substantially increase local production capacity while significantly reducing the cost of cell therapy.
  • In 2021, SCG collaborated with the Cell Therapy Facility of Singapore Health Sciences Authority (HSA-CTF) to validate its proprietary closed and automated cell therapy manufacturing system.
  • "Apart from the cGMP facility, SCG Cell Therapy is also opening an R&D centre to facilitate the research of its pipeline of cell therapy product candidates.

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US

Retrieved on: 
Thursday, July 6, 2023
Yee, Patent, Antigen, Cytomics, IPSC, NKT, STAR, National University Hospital, Alberta Enterprise Group, United States patent law, Innovation, Research, Immunotherapy, NUH, Assistant, CAR, Cancer, Hematological Cancer Research Investment and Education Act, Gamma delta T cell, Biological patents in the United States, Patient, Risk, A*STAR, Same, Outline of health sciences, Health Sciences Authority, Therapy, T, HSA, NKG2D, Vaccine

Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.

Key Points: 
  • Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.
  • CytoMed holds an exclusive, worldwide license, for use on immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive γδ NKT cells for cancer treatments.
  • A patent for this proprietary technology has already been granted in Japan and this asset is under preclinical development.

Innovative paper-like, battery-free, AI-enabled sensor for holistic wound monitoring

Retrieved on: 
Tuesday, June 27, 2023
Science and technology in Asia, Infection, Science, PETAL, Nanyang Technological University, Science Advances, National University of Singapore, Electronics, Classification, Oxygen, Glucose, Multiplexing, National university, Scar, Research, Temperature, Multimedia, Burn, Biomarker, Interleukin 6, Yale-NUS College, Pain, Uric acid, Hospital, Patient, A*STAR, Algorithm, Artificial intelligence, AI, Trauma, PH, NUS, Skin, Wound healing, Nursing, Medical imaging, Instrumentation, Engineering

SINGAPORE, June 27, 2023 /PRNewswire/ -- Timely and effective monitoring of wound healing status is critical to wound care and management.

Key Points: 
  • SINGAPORE, June 27, 2023 /PRNewswire/ -- Timely and effective monitoring of wound healing status is critical to wound care and management.
  • Wound infections are mostly diagnosed via swabbing followed by a bacteria culture which involves long waiting time and does not provide timely wound diagnosis.
  • These biomarkers were carefully selected to effectively assess wound inflammation, infection as well as the condition of the wound environment.
  • The bottom wound contact layer gently attaches the sensor patch to the skin and protects the wound bed from direct contact with the sensor panel, to minimise wound tissue disruptions.